Patients with adult T-cell leukemia/lymphoma (ATLL) who were treated with  Poteligeo (mogamulizumab), an anti-CCR4 monoclonal antibody,  may be at higher risk for serious graft-versus-host disease (GvHD)-related complications  following allogeneic hematopoietic stem ... Read more